NCT00428896View on ClinicalTrials.gov

A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Breast Cancer
Interventions
DRUG

ZD1839

ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months

Trial Locations (1)

71110

University Hospital of Crete, Heraklion

All Listed Sponsors
lead

University Hospital of Crete

OTHER

NCT00428896 - A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer | Biotech Hunter | Biotech Hunter